Skip to main content
NCBI home page
British Heart Journal logoLink to British Heart Journal
. 1984 May;51(5):530–538. doi: 10.1136/hrt.51.5.530

Acute intravenous and sustained oral treatment with the beta1 agonist prenalterol in patients with chronic severe cardiac failure.

P J Currie, M J Kelly, K Middlebrook, J Federman, E Sainsbury, J Ashley, A Pitt
PMCID: PMC481544  PMID: 6326784

Abstract

Prenalterol, a beta1 agonist, was given in a single blind acute intravenous study to seven patients with cardiac failure (New York Heart Association class II and III). It was then given in a double blind crossover study of sustained oral prenalterol to six of them. As a result of dose titration studies the oral dose of prenalterol given was 100 mg twice a day in all patients. Erect bicycle sprint tests were performed to exercise tolerance before and after treatment had been started. Cardiac function was assessed at rest and during graded supine bicycle exercise by determining haemodynamic indices using a Swan-Ganz catheter and radionuclide left ventricular ejection fractions. In the intravenous study cardiac function was assessed at rest and during exercise after a control infusion of dextrose and after an infusion of 5 mg prenalterol. In the oral crossover study a placebo or prenalterol were given for two periods of two weeks; at the end of each period exercise tolerance was measured and cardiac function assessed at rest and during exercise. Throughout the study period there was no change in symptoms, medication, or exercise tolerance. Intravenous prenalterol significantly improved cardiac function; left ventricular ejection fraction and cardiac index increased and left ventricular filling pressure fell both at rest and during exercise. Sustained oral treatment with prenalterol, however, did not improve resting left ventricular filling pressure or left ventricular ejection fraction at rest or during exercise but did increase heart rate at rest, and mean blood pressure and peripheral vascular resistance at rest and during exercise; in fact, during exercise left ventricular filling pressure was significantly increased while cardiac index and stroke volume index were decreased by prenalterol. Sustained oral treatment with prenalterol did not have the beneficial effects on cardiac function produced by intravenous treatment and in fact had deleterious effect on the measured indices of cardiac function during exercise.

Full text

PDF
530

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Awan N. A., Needham K. E., Evenson M. K., Win A., Mason D. T. Hemodynamic actions of prenalterol in severe congestive heart failure due to chronic coronary disease. Am Heart J. 1981 Feb;101(2):158–161. doi: 10.1016/0002-8703(81)90659-1. [DOI] [PubMed] [Google Scholar]
  2. Bailey I. K., Anderson S. D., Rozea P. J., Bernstein L., Nyberg G., Korner P. I. Effect of beta-adrenergic blockade with alprenolol on ST-segment depression and circulatory dynamics during exercise in patients with effort angina. Am Heart J. 1976 Oct;92(4):416–426. doi: 10.1016/s0002-8703(76)80040-3. [DOI] [PubMed] [Google Scholar]
  3. Colucci W. S., Alexander R. W., Williams G. H., Rude R. E., Holman B. L., Konstam M. A., Wynne J., Mudge G. H., Jr, Braunwald E. Decreased lymphocyte beta-adrenergic-receptor density in patients with heart failure and tolerance to the beta-adrenergic agonist pirbuterol. N Engl J Med. 1981 Jul 23;305(4):185–190. doi: 10.1056/NEJM198107233050402. [DOI] [PubMed] [Google Scholar]
  4. Currie P. J., Kelly M. J., McKenzie A., Harper R. W., Lim Y. L., Federman J., Anderson S. T., Pitt A. Oral beta-adrenergic blockade with metoprolol in chronic severe dilated cardiomyopathy. J Am Coll Cardiol. 1984 Jan;3(1):203–209. doi: 10.1016/s0735-1097(84)80449-0. [DOI] [PubMed] [Google Scholar]
  5. Erbel R., Meyer J., Lambertz H., Schweizer P., Voelker W., Krebs W., Braun G., Effert S. Hemodynamic effects of prenalterol in patients with ischemic heart disease and congestive cardiomyopathy. Circulation. 1982 Aug;66(2):361–369. doi: 10.1161/01.cir.66.2.361. [DOI] [PubMed] [Google Scholar]
  6. Fitzpatrick D., Ikram H., Nicholls M. G., Espiner E. A. Hemodynamic, hormonal and electrolyte responses to prenalterol infusion in heart failure. Circulation. 1983 Mar;67(3):613–619. doi: 10.1161/01.cir.67.3.613. [DOI] [PubMed] [Google Scholar]
  7. Garcia R., Jennings J. M. Pheochromocytoma masquerading as a cardiomyopathy. Am J Cardiol. 1972 Apr;29(4):568–571. doi: 10.1016/0002-9149(72)90452-3. [DOI] [PubMed] [Google Scholar]
  8. Hutton I., Murray R. G., Boyes R. N., Rae A. P., Hillis W. S. Haemodynamic effects of prenalterol in patients with coronary heart disease. Br Heart J. 1980 Feb;43(2):134–137. doi: 10.1136/hrt.43.2.134. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Johnsson G., Jordö L., Lundborg P., Rönn O., Welin-Fogelberg I., Wikstrand J. Haemodynamic and tolerance studies in man of a new, orally active, selective beta1-adrenoceptor agonist H 80/62. Eur J Clin Pharmacol. 1978 May 31;13(3):163–170. doi: 10.1007/BF00609978. [DOI] [PubMed] [Google Scholar]
  10. Kalff V., Kelly M. J., Jennings G. L., Lim Y. L., Anderson S. T., Korner P. I., Harper R. W., Pitt A. The radionuclide assessment of left ventricular function using graded exercise in normal subjects. Aust N Z J Med. 1980 Oct;10(5):533–539. doi: 10.1111/j.1445-5994.1980.tb04972.x. [DOI] [PubMed] [Google Scholar]
  11. Kirlin P. C., Pitt B. Hemodynamic effects of intravenous prenalterol in severe heart failure. Am J Cardiol. 1981 Mar;47(3):670–675. doi: 10.1016/0002-9149(81)90553-1. [DOI] [PubMed] [Google Scholar]
  12. Lefkowitz R. J. Direct binding studies of adrenergic receptors: biochemical, physiologic, and clinical implications. Ann Intern Med. 1979 Sep;91(3):450–458. doi: 10.7326/0003-4819-91-3-450. [DOI] [PubMed] [Google Scholar]
  13. Plummer A. L. Drug tolerance to beta2 adrenergic agents. Chest. 1978 Jun;73(6 Suppl):994–996. doi: 10.1378/chest.73.6.994. [DOI] [PubMed] [Google Scholar]
  14. Schaffer M. S., Zuberbuhler P., Wilson G., Rose V., Duncan W. J., Rowe R. D. Catecholamine cardiomyopathy: an unusual presentation of pheochromocytoma in children. J Pediatr. 1981 Aug;99(2):276–279. doi: 10.1016/s0022-3476(81)80477-5. [DOI] [PubMed] [Google Scholar]
  15. Tweddel A. C., Murray R. G., Pearson D., Martin W., Hutton I. Cardiovascular effects of prenalterol on rest and exercise haemodynamics in patients with chronic congestive cardiac failure. Br Heart J. 1982 Apr;47(4):375–380. doi: 10.1136/hrt.47.4.375. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Unverferth D. A., Blanford M., Kates R. E., Leier C. V. Tolerance to dobutamine after a 72 hour continuous infusion. Am J Med. 1980 Aug;69(2):262–266. doi: 10.1016/0002-9343(80)90387-3. [DOI] [PubMed] [Google Scholar]
  17. Waagstein F., Reiz S., Ariniego R., Hjalmarson A. Clinical results with prenalterol in patients with heart failure. Am Heart J. 1981 Sep;102(3 Pt 2):548–554. doi: 10.1016/0002-8703(81)90743-2. [DOI] [PubMed] [Google Scholar]
  18. Weiss A., Pfister B., Imhof P., Degen P. H., Burckhardt D., Dubach U. C. Haemodynamic effects, plasma concentrations and tolerance of orally administered prenalterol in man. Eur J Clin Pharmacol. 1980 Nov;18(5):383–390. doi: 10.1007/BF00636789. [DOI] [PubMed] [Google Scholar]
  19. Williams R. S. Selectivity of prenalterol for adrenergic receptor subtypes: a potential mechanism of inotropic selectivity. J Cardiovasc Pharmacol. 1983 Mar-Apr;5(2):266–271. doi: 10.1097/00005344-198303000-00017. [DOI] [PubMed] [Google Scholar]

Articles from British Heart Journal are provided here courtesy of BMJ Publishing Group

RESOURCES